Capitol Health (ASX:CAJ) secured shareholder approval on Monday relating to the company's proposed merger with Integral Diagnostics (ASX:IDX) through a scheme of arrangement, according to a same-day filing with the Australian bourse.
About 95% of the shareholders were present and voting during the meeting with 99.9% of all votes in favor of the resolution, the filing said.
Integral Diagnostics has been engaged with the Australian Competition and Consumer Commission regarding the potential divestment and is awaiting informal merger clearance from the regulator.
Once Integral Diagnostics receives merger clearance from the Australian Competition and Consumer Commission, the company will apply to the Court for approval of the scheme.
Earlier, Capitol Health said the Federal Court of Australia will hear on Dec. 4 its application seeking the approval of the scheme.
Shares of Capitol Health and Internal Diagnostics each fell 3% on market close.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。